RESEARCH REPORT
Reinventing biopharma from lab to line
Fueling smarter, faster and scalable biopharma production with intelligent technologies.
5-MINUTE READ
February 10, 2026
In brief
- Biologics now represents 55% of the clinical pipeline, and the increasing complexity of molecules puts pharmaceutical manufacturing under pressure.
- 64% of drug-launch delays as analyzed across FDA CRLs from 2019-2024 were due to chemistry, manufacturing and control issues.
- Strong data and infrastructure foundations can accelerate time to market, cut costs, and boost supply chain efficiency.
Intelligent technologies accelerate progress in biopharma manufacturing
We conducted comprehensive research on progress of digital transformation in biopharmaceutical manufacturing and technical operations.
Manufacturing is now on the critical path to delivering essential medicines to patients, a pivotal moment that demands tighter integration from lab to line to ensure speed, reliability, and quality.
By scaling intelligent technologies across the product lifecycle—from robotic high throughput process design to AI-augmented real-time analytics and decision making— biopharma leaders can reduce costs, accelerate launches and build more reliable, adaptive manufacturing systems.
However, only a few companies realize these benefits. Most find themselves stuck in the middle” of their digital journey. 35% of surveyed executives indicated their companies function as “connected organizations” in biopharma manufacturing/technical operations.
The roadblocks on the way to scaling digital initiatives
Despite visible progress, most biopharma companies encounter recurring obstacles when attempting to scale digital initiatives:
- Digital pilots are often limited to low-risk, low-impact areas, restricting broader transformation.
- Core data infrastructure and systems remain unprepared to support large-scale digital programs.
- Digital efforts are frequently siloed within individual functions, resulting in fragmented initiatives.
The outcome is fragmented solutions with limited return on investment, digital initiatives that cannot scale, and a growing number of “digital dead ends.” These disconnects widen the gap between ambition and execution. If left unresolved, the industry’s digital momentum risks stalling, potentially leading to costly rework and lost opportunities.
The challenge for biopharma leaders is no longer whether manufacturing transformation is needed, but how rapidly they can overcome these barriers to scale successful innovations, incorporating intelligent technologies into the product development lifecycle enables organizations to streamline processes at unprecedented scale and speed, helping bridge the gap from vision to execution.
Source: Accenture Analysis
Reinventing the product development life cycle with intelligent technologies
By combining human capital and intelligent technologies, biopharma companies have the potential to revolutionize the product development lifecycle, especially in advanced modalities. AI in drug development has already shown promise in accelerating development timelines, moving from concept to clinical trials in mere months rather than years.
To fully capture the economic benefits of accelerated R&D, companies must optimize the entire product lifecycle, from product development labs to production lines —and intelligent technologies can play a pivotal role across every function at every stage of technical operations.
Our project work with clients, industry case studies and technical literature highlight the following benefits of implementing intelligent technologies in product development.
- Reduced time-to-market by up to 40%
- Improved throughput in process development by 30%
- Yield enhancements of over 400% in upstream (cell culture) processes, with further cumulative gains possible across downstream and conjugation steps, lowering costs, carbon footprint and future capacity needs.
- Batch lead time reduction of up to 50%, minimizing work-in-progress inventory.
- Increased efficiency in deviation investigations, cutting analysis time by over 50%
A roadmap for unlocking the value of digital
To scale innovations, biopharma companies need an interconnected system that puts people, data and technology in the center. Only then can they fully embrace data digitalization and intelligent technologies.
A rock-solid foundation like this allows them to build truly resilient operations. To ride out geopolitical policy swings and supply-chain shocks, keep pace with AI-accelerated development timelines, and manage complex pipelines, pharma companies should focus on three key areas:
The future of biopharma production is technology driven
As biopharma companies adopt intelligent technologies across the full value chain from lab to line, there is real opportunity to boost revenue, accelerate the launch curve and extend the life cycle of therapies. This is a fundamental shift that will change how companies view and manage their operations, moving beyond physical expansion by building new plants or labs to a ‘lifecycle of the future’.
Companies leading the transformation will reap the benefits of the change. They will lead with value, strengthen their digital core and reinvent workflows, redefining how they operate, drive profitability and ultimately benefit patients.
Contributors
The authors would like to thank the following individuals for their contributions to the report:
- Brendan Hughes Ph.D BPHughesCMCConsulting
- Barry Heavey Former Accenture Life Sciences Industry X and Supply Chain & Operations, Global Lead. Now Head of Data Analytics, Sartorius
- Amanda Rubin, Bilal Butt, Camille Planty, Ciara Mc Nally, Joanna Lisiecka, Kamila Ochedalska-Szymanska and Kristina Tomes
Sources
1 AI Approach to Maximizing Value in Manufacturing
2 Making Self-funding Supply Chains Real with AI
3 From jobs to value - reinventing talent strategy with a human+ AI workforce